secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001213900-24-068589
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix Q2 net loss $14.2M; DefenCath sales $0.8M initial, outpatient QTD $5.2M
--------------------------------------------------------------------------------

- Q2 net loss $14.2M ($0.25/share) vs $11.3M loss ($0.25/share) a year ago, driven by higher operating expenses.
- DefenCath net sales $0.8M for partial quarter since April 15 inpatient launch; outpatient QTD sales $5.2M as of Aug 13.
- Operating expenses $15.6M in Q2 (+32% YoY) from commercial launch costs; R&D down 86% post-approval.
- Cash and short-term investments $45.6M at June 30, sufficient for at least 12 months.
- Submitted TPN study protocol to FDA; patient enrollment expected to begin Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390024068589/0001213900-24-068589-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390024068589/ea0211338-8k_cormed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-068589

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer